[Interview] The Current Status Of AI In Drug Discovery And Looking Forward Into 2018
Without a doubt, the area of artificial intelligence (AI) has been a sensation lately -- judging by the amount of hype around this topic. But the hype is not a guarantee of a real breakthrough, which is defined by facts and measurable achievements, not just loud statements.
If it is not enough, here is a list of pretty much everything AI can do already today, speaking in practical terms. With this, it is becoming obvious that the progress in the AI space is quite real and the practical benefits are quite tangible, albeit there are a lot of technological and organizational challenges to overcome yet.
What is important to realize, though, is that the AI technologies hold a substantial disruptive potential, which can (possibly) transform the whole industries and redefine status quo. It is something to keep in mind if we talk about maintaining a long-term innovative competitiveness.
At BioPharmaTrend we are striving to find out what the AI-driven innovation really means for the biopharmaceutical industry, and drug discovery research in particular.
I decided to find out answers to some of the intriguing questions about AI in drug discovery/biopharma from the first hands.
Dr. Alex Zhavoronkov, co-founder, and CEO of Insilico Medicine -- a company leading the way in the applications of AI to drug discovery and age-related research, agreed to comment on what has been going on in this area lately, and what to expect in 2018.
This content available exclusively for BPT Mebmers
AI will transform drug discovery in a big way. But without the experimental validation there will be no trust in the tech. Nutraceuticals and skin creams are good ideas.
Leave a Reply cancel reply
Your email address will not be published. Required fields are marked *